Cochrane group skeptical about latest Roche pledges

Cochrane group skeptical about latest roche pledges
Following requests from Cochrane researchers, Roche has pledged to release full clinical study reports for Tamiflu, although there appear to be conditions attached, according to correspondence published in BMJ.

(HealthDay)—Following requests from Cochrane researchers, Roche has pledged to release full clinical study reports for Tamiflu, although there appear to be conditions attached, according to correspondence published in BMJ.

Peter Doshi, Ph.D., from the Johns Hopkins University School of Medicine in Baltimore, along with colleagues from the Cochrane group, recently corresponded with Roche as part of the 's open data campaign designed to encourage Roche to honor its 2009 commitment to make the full clinical study reports for 10 trials of Tamiflu available for independent review.

Noting that Roche recently pledged to release full clinical study reports as part of the data transparency program, the authors question these new promises. Roche plans to allow researchers access to a secure system, following agreement, rather than the requested independent review. Three of the four advisors chosen to lead Roche's advisory board, which will grant access to data, have recent financial ties to Roche. In addition, there has been no attempt to correct the scientific record following the 2003 Roche-authored paper claiming the opposite of the U.S. conclusion that has not been shown to prevent serious bacterial complications of influenza.

"Despite our repeated requests for those data, has yet to provide even a single full study report," Doshi writes. "We are independent scientists, not regulators. Doing our own analysis, not dictated by others, is key to what makes us independent."

More information: More Information

add to favorites email to friend print save as pdf

Related Stories

Tamiflu touted for child use

Nov 16, 2007

The maker of the anti-viral Tamiflu said the drug is effective for treatment and prevention of influenza in young children.

Recommended for you

FDA OKs Cubist antibiotic for serious infections

Dec 20, 2014

The Food and Drug Administration has approved a new medicine to fight complex infections in the abdomen and urinary tract, the fourth antibiotic the agency has approved since May.

Xtoro approved for swimmer's ear

Dec 18, 2014

(HealthDay)—Xtoro (finafloxacin otic suspension) eardrops have been approved by the U.S. Food and Drug Administration to treat swimmer's ear, clinically known as acute otitis externa.

Drug interaction identified for ondansetron, tramadol

Dec 18, 2014

(HealthDay)—In the early postoperative period, ondansetron is associated with increased requirements for tramadol consumption, according to a review and meta-analysis published online Dec. 10 in Anaesthesia.

New system targets germs in donated blood plasma

Dec 17, 2014

(HealthDay)—A new system designed to eliminate germs in donated blood plasma and reduce the risk of transmitting a plasma-borne infection has been approved by the U.S. Food and Drug Administration.

User comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.